---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-016758"
form_type: "8-K"
ticker: "IDYA"
cik: "0001676725"
company_name: "IDEAYA Biosciences, Inc."
filed_at: "2024-02-20T23:59:59+00:00"
generated_at: "2026-06-05T23:13:24.336265+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# IDYA reports Q4 net loss $34M, cash $632.6M; multiple 2024 milestones

## Summary
- Cash $632.6M at Dec 31, 2023; Jan 2024 ATM raised ~$352M gross ($342.3M net); runway into 2028.
- Q4 net loss $34.0M (vs $24.2M); FY 2023 net loss $113.0M (vs $58.7M). R&D spend $38.8M Q4.
- Targeting two Phase 2 efficacy updates for darovasertib in neoadjuvant uveal melanoma mid-2024, plus FDA guidance.
- Gilead collaboration to evaluate IDE397 + Trodelvy in MTAP-deletion bladder cancer; FPI mid-2024.
- Werner helicase IND filing targeted 2024; $7M milestone on clearance. GSK collaboration.

## SEC filing metadata
- accession: 0000950170-24-016758
- form_type: 8-K
- ticker: IDYA
- cik: 0001676725
- company_name: IDEAYA Biosciences, Inc.
- filed_at: 2024-02-20T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676725/000095017024016758/0000950170-24-016758-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676725/000095017024016758/idya-20240220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-016758
- JSON: https://secwatch.observer/filing/0000950170-24-016758.json
- Plain text: https://secwatch.observer/filing/0000950170-24-016758.txt

## Key facts
- Earnings Releases
  IDEAYA Biosciences, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: On February 20, 2024, IDEAYA Biosciences, Inc. (the “Company”) announced its financial results for the fourth quarter and full year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1676725/000095017024016758/0000950170-24-016758-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.